A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Eli Lilly and Company
City of Hope Medical Center
MOMA Therapeutics
Pheon Therapeutics
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kestrel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
National Cancer Institute (NCI)
AbbVie
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
City of Hope Medical Center
Nammi Therapeutics Inc
Revolution Medicines, Inc.
University of California, San Diego
Pfizer
M.D. Anderson Cancer Center
PanTher Therapeutics
Alterome Therapeutics, Inc.
Arcus Biosciences, Inc.
Amgen
NYU Langone Health
ImmunityBio, Inc.
M.D. Anderson Cancer Center
Institut Paoli-Calmettes
Arbele Limited
UNC Lineberger Comprehensive Cancer Center
RasCal Therapeutics, Inc.
Continuity Biosciences, LLC
Washington University School of Medicine
Tomsk National Research Medical Center of the Russian Academy of Sciences
Institute of Cancer Research, United Kingdom
University of California, Davis
ViroMissile, Inc.
Erasca, Inc.
Changhai Hospital
Washington University School of Medicine